CONCLUSIONS
This feasibility study suggests that micronutrient abnormalities were present in ninety percent of study patients. Subclinical micronutrient deficiency can occur in patients who do not appear malnourished. Forty percent of patients are receiving some form of micronutrient supplementation. It is feasible to document toxicity and adverse events on therapy. This is especially true if patients are enrolled in a therapeutic clinical trial. The role of micronutrient supplementation to assess benefit or harm is required. The role of micronutrients from a cancer control perspective requires further basic and clinical research28,29